Mackie Ken
Department of Anesthesiology and Physiology, University of Washington School of Medicine, Seattle, WA 98195-6540, USA.
Annu Rev Pharmacol Toxicol. 2006;46:101-22. doi: 10.1146/annurev.pharmtox.46.120604.141254.
CB1 and CB2 cannabinoid receptors are the primary targets of endogenous cannabinoids (endocannabinoids). These G protein-coupled receptors play an important role in many processes, including metabolic regulation, craving, pain, anxiety, bone growth, and immune function. Cannabinoid receptors can be engaged directly by agonists or antagonists, or indirectly by manipulating endocannabinoid metabolism. In the past several years, it has become apparent from preclinical studies that therapies either directly or indirectly influencing cannabinoid receptors might be clinically useful. This review considers the components of the endocannabinoid system and discusses some of the most promising endocannabinoid-based therapies.
CB1和CB2大麻素受体是内源性大麻素（内源性大麻素）的主要靶点。这些G蛋白偶联受体在许多过程中发挥重要作用，包括代谢调节、渴望、疼痛、焦虑、骨骼生长和免疫功能。大麻素受体可以直接被激动剂或拮抗剂作用，也可以通过操纵内源性大麻素代谢间接起作用。在过去几年中，临床前研究表明，直接或间接影响大麻素受体的疗法可能具有临床应用价值。本文综述了内源性大麻素系统的组成部分，并讨论了一些最有前景的基于内源性大麻素的疗法。
